<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389919</url>
  </required_header>
  <id_info>
    <org_study_id>BM-MSC-01</org_study_id>
    <nct_id>NCT03389919</nct_id>
  </id_info>
  <brief_title>Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT</brief_title>
  <official_title>EFFECTIVENESS AND SAFETY OF INTRAOSSEOUS ADMINISTRATION OF MESENCHYMAL STORMAL CELLS FOR PRIMARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow
      niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches
      in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since
      only few MSCs reach the BM after intravenous injection, MSCs were implanted into the iliac
      spine. Preliminary results suggest that MSCs participate in the restoration of niches for
      donor hematopoietic cells or have an immunomodulatory effect, preventing repeated rejection
      of the graft. Perhaps intraosseous implantation of MSCs contributes to the success of the
      second transplantation of hematopoietic stem cells and patient survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment</measure>
    <time_frame>28-day</time_frame>
    <description>Engraftment</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mesenchymal Stem Cell Transplantation</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC administration (intraosseal)</intervention_name>
    <description>MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with primary graft failure after allo-HSCT

          -  Available MSC for this patient

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BMT department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
      <phone>+79161487131</phone>
      <email>kuzlara@rambler.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Parovichnikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Elena N.Parovichnikova</investigator_full_name>
    <investigator_title>Head of BMT department</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

